Tagged with ARM

Pharma Singapore, though conscious of its limitations, has been able to leverage its key assets of location, infrastructure and local talent in order to become the business hub for the entire region, with pharma and biotech as key components in its success. Singapore is … an attractive investment destination, especially for the…

Pharma Daniel Pardo Bejarano, CEO of BOMI Mexico, details the competitive advantages and the unique business approach that make BOMI the logistics partner of choice of the Mexican healthcare industry, while the fast-growing company holds the ambition to double the size of its business over the next four years. After more…

Pharma With nearly €4 billion of capital investment in large molecule manufacturing underway, Ireland’s strategy to become a premier destination for biologics FDI has proven to be successful, according to BioPharmaChem Ireland director Matt Moran. Yet, Ireland today is much more than a manufacturing hub, and is well on its way to…

Pharma The following map shows the importance of the pharmaceutical industry to the highly regionalised Italian industry. Lombardy in the North of Italy employs 27,000 people in pharmaceuticals and is ranked number one for pharma and biotech firms. Click here to read more articles and interviews from Italy, and to download…

Biotech The chairman of BioSingapore, Dr. Siew Hwa Ong, discusses the opportunities and challenges facing biotech SMEs in Singapore, government efforts to enhance the business environment for these SMEs, and facilitating more collaboration between companies as the most prominent pathway for future development. Could you please introduce yourself to our international…

Pharma Teodoro Padilla, Executive Director at the Pharmaceutical and Healthcare Association of the Philippines, and Reiner Gloor, Advisor and Honorary Member, discuss the current objectives and goals of the association, how they are adapting to recent changes in the country’s healthcare landscape, and the impact of the rise of generics. To begin, could…

Pharma The below chart shows the sources of funding for R&D investment in Italy, with only 7% of total investment originating from pharmaceutical and health-oriented biotech. Click here to read more articles and interviews from Italy, and to download the latest free pharma report on the country.

Pharma The Singapore Association of Pharmaceutical Industries’ (SAPI) recently appointed president, Ti Hwei How highlights several unique attributes that distinguish Singapore’s renowned healthcare system from others around the world, while delineating three potential avenues for expanding patient access to innovative medicines. To begin, Ti Hwei, how would you characterize the specificities…

Pharma The executive director of A*STAR’s Biomedical Research Council, Dr. Benjamin Seet highlights several remarkable milestones that the organization has been able to achieve since its inception, while underscoring how cultivating deep levels of expertise will carry Singapore’s biomedical sciences sector into its next phase of development. In a few words,…

Pharma France provides a unique environment for dermo-cosmetics companies such as Pierre Fabre, Uriage, and Galderma to thrive in terms of the industry’s historical legacy in the country, abundant natural resources, and a tradition of openness and understanding of dermatology. [France is] a unique environment for the growth of dermo-cosmetic brands. French dermatologists have a…

Pharma The expansion of universal healthcare coverage and significant growth in the use and acceptance of generics across the Philippines pose a significant challenge to the innovative medicines industry but also offers a wealth of opportunities for both international and domestic players. The Philippines now utilizes low-cost generics more than any…

Pharma The following chart shows the number of clinical trials in Italy per year. Peaking in 2008 and slumping slightly shortly after, the numbers have returned to robust levels with 550+ trials in total in 2013 and 250+ important Phase I and II trials. Click here to read more articles and…